No consistency in endophthalmitis prophylaxis

Article

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.

Patel Gordon-Bennett of the department of ophthalmology at Hinchingbrooke Hospital, Cambridgeshire, UK and colleagues conducted a telephone interview survey with 800 staff from ophthalmic training units across the UK between October and November 2005.

The team found that 99.4% of surgeons (n=795) used a preoperative preparation of povidone-iodine on the skin; 69.8% (n=558) instilled povidone-iodine into the conjunctival sac; and 5.9% (n=47) administered antibiotic eyedrops. During surgery, 17.8% (n=142) administered intracameral antibiotics: 66.4% (n=531) administered subconjunctival cefuroxime, 6.0% (n=48) administered routine gentamycin and 4.9% (n=39) administered alternative subconjunctival antibiotics; 16.8% (n=134) administered topical drops as a single dose. Combination steroid/neomycin drops were used by 64.4% of surgeons (n=515) postoperatively; 26.6% (n=213) administered separate drops.

The study revealed wide variation in the preventative measures employed by surgeons. The most frequently deployed methods of endophthalmitis prophylaxis are administrations of subconjunctival and intracameral cefuroxime.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.